Responses
Scientific Abstracts
Late Breaking Abstracts
Late Breaking Abstract Session
LB0004 Efficacy and safety of nnc0109-0012 (anti-IL-20 MAB) in patients with rheumatoid arthritis: Results from a phase 2a trial
Compose a Response to This Article
Other responses
No responses have been published for this article.